Boehringer Ingelheim is one of the world’s leading pharmaceutical companies in the treatment of respiratory diseases. Our central aim is to leverage our longstanding expertise in respiratory medicine to relentlessly target indications with high unmet medical need.

Our Respiratory Diseases Partnering Focus
We are further strengthening our existing portfolio for the treatment of respiratory diseases through in-licensing and external collaborations at research, pre-clinical and clinical stages.

Specifically, our areas of partnering interest include:

**IPF/PF-ILD**
- Block of pro-fibrotic signaling beyond standard of care

**Chronic Obstructive Pulmonary Disease**
- Stop/slowdown of small airway diseases

**Asthma**
- Treatment of severe non-Th2 asthma

**Acute Respiratory Distress Syndrome and Cystic fibrosis**

Furthermore we are interested in the following research areas:

- Repair of epithelial barrier functions
- Block of inflammation, including inactivation/depletion of mast cells
- Modulation of macrophage dysfunction, like reduced phagocytosis.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

**Working together for better health**

For more information please contact our BD&L team:
Dr. Silke Hobbie
silke.hobbie@boehringer-ingelheim.com

Dr. Peter Seither
peter.seither@boehringer-ingelheim.com